Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1179-2027
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective ; volume:39 ; number:11 ; day:8 ; month:10 ; year:2021 ; pages:1343-1354 ; date:11.2021
PharmacoEconomics ; 39, Heft 11 (8.10.2021), 1343-1354, 11.2021

Creator
Alsumali, Adnan
Djatche, Laurence M.
Briggs, Andrew Harvey
Liu, Rongzhe
Diakite, Ibrahim
Patel, Dipen
Wang, Yufei
Lautsch, Dominik
Contributor
SpringerLink (Online service)

DOI
10.1007/s40273-021-01091-w
URN
urn:nbn:de:101:1-2021122917452947952340
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:22 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Alsumali, Adnan
  • Djatche, Laurence M.
  • Briggs, Andrew Harvey
  • Liu, Rongzhe
  • Diakite, Ibrahim
  • Patel, Dipen
  • Wang, Yufei
  • Lautsch, Dominik
  • SpringerLink (Online service)

Other Objects (12)

Clinical and Economic Burden of Chronic Heart Failure and Reduced Ejection Fraction Following a Worsening Heart Failure Event

Clinical and Economic Burden of Chronic Heart Failure and Reduced Ejection Fraction Following a Worsening Heart Failure Event

Comment on “Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective”

Comment on “Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective”

Worsening effect of testosterone deficiency on males with heart failure with preserved ejection fraction

Worsening effect of testosterone deficiency on males with heart failure with preserved ejection fraction

Vericiguat for Heart Failure with Reduced Ejection Fraction

Vericiguat for Heart Failure with Reduced Ejection Fraction

Biomarkers in heart failure with preserved ejection fraction

Biomarkers in heart failure with preserved ejection fraction

Comorbidities in heart failure with preserved ejection fraction

Comorbidities in heart failure with preserved ejection fraction

Heart failure

Heart failure

Atrial fibrillation and risk of progressive heart failure in patients with preserved ejection fraction heart failure

Atrial fibrillation and risk of progressive heart failure in patients with preserved ejection fraction heart failure

Advance Care Planning (ACP) in Medicare Beneficiaries with Heart Failure

Advance Care Planning (ACP) in Medicare Beneficiaries with Heart Failure

Animal models of heart failure with preserved ejection fraction

Animal models of heart failure with preserved ejection fraction

Heart Failure with Preserved Ejection Fraction—a Concise Review

Heart Failure with Preserved Ejection Fraction—a Concise Review

SGLT2 inhibitors in heart failure with reduced ejection fraction

SGLT2 inhibitors in heart failure with reduced ejection fraction

Related objects